Trihexyphenidyl treatment of clozapine-induced hypersalivation.
The objective of this study was to investigate the efficacy of the anticholinergic agent trihexyphenidyl in the treatment of clozapine-induced hypersalivation. Fourteen chronic schizophrenic patients who exhibited nocturnal hypersalivation during clozapine treatment were coadministered trihexyphenidyl (5-15 mg/day, at bedtime) for 15 days. Salivation was assessed by a single-item 5-point scale. A reduction of 44% in the reported nocturnal hypersalivation was observed after trihexyphenidyl treatment. These results indicate that at least some chronic schizophrenic patients with clozapine-induced nocturnal hypersalivation may benefit from anticholinergic treatment.
Spivak
B
B
Ness Ziona Mental Health Center, Israel.
Adlersberg
S
S
Rosen
L
L
Gonen
N
N
Mester
R
R
Weizman
A
A
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D003024:Clozapine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy; D012798:Sialorrhea / Q000139:chemically induced* / Q000188:drug therapy*; D014282:Trihexyphenidyl / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D018727:Muscarinic Antagonists; D014282:Trihexyphenidyl; D003024:Clozapine